The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis

Adams, 2005, Spasticity after spinal cord injury, Spinal Cord, 43, 577, 10.1038/sj.sc.3101757 Agarwal, 2007, Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors, Nature Neuroscience, 10, 870, 10.1038/nn1916 Al-Izki, 2011, Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis, Multiple Sclerosis, 17, 939, 10.1177/1352458511400476 Al-Izki, 2009, Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography, Multiple Sclerosis, 15, 795, 10.1177/1352458509104594 Ahn, 2011, Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain, Journal of Pharmacology and Experimental Therapeutics, 338, 114, 10.1124/jpet.111.180257 Aragona, 2009, Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study, Clinical Neuropharmacology, 32, 41, 10.1097/WNF.0b013e3181633497 Arévalo-Martín, 2003, Therapeutic action of cannabinoids in a murine model of multiple sclerosis, Journal of Neuroscience, 23, 2511, 10.1523/JNEUROSCI.23-07-02511.2003 Baker, 2011, Critical appraisal of animal models of multiple sclerosis, Multiple Sclerosis, 17, 647, 10.1177/1352458511398885 Baker, 2007, Models of multiple sclerosis, Advances in Clinical Neuroscience and Rehabilitation, 6, 10 Baker, 1990, Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice, Journal of Neuroimmunology, 28, 261, 10.1016/0165-5728(90)90019-J Baker, 2000, Cannabinoids control spasticity and tremor in a multiple sclerosis model, Nature, 404, 84, 10.1038/35003583 Baker, 2001, Endocannabinoids control spasticity in a multiple sclerosis model, FASEB Journal, 15, 300, 10.1096/fj.00-0399fje Baker D, Pryce G, Giovannoni G, Thompson AJ. Methods for treatment of inflammatory diseases using CT-3 or analogs thereof WO; 2004, 100893. Barann, 2002, Direct inhibition by cannabinoids of human 5-HT(3A) receptors: probable involvement of an allosteric modulatory site, British Journal of Pharmacology, 137, 589, 10.1038/sj.bjp.0704829 Basavarajappa, 2007, Critical enzymes involved in endocannabinoid metabolism, Protein & Peptide Letters, 14, 237, 10.2174/092986607780090829 Beltramo, 1997, Functional role of high-affinity anandamide transport, as revealed by selective inhibition, Science, 277, 1097 Berghuis, 2007, Hardwiring the brain: endocannabinoids shape neuronal connectivity, Science, 316, 1212, 10.1126/science.1137406 Bilsland, 2006, Manipulation of the endocannabinoid system ameliorates disease symptoms in the SOD1G93A mouse model of ALS, FASEB Journal, 20, 1003, 10.1096/fj.05-4743fje Bittner, 2009, TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system, Brain, 132, 2501, 10.1093/brain/awp163 Blankman, 2007, A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol, Chemistry & Biology, 14, 1347, 10.1016/j.chembiol.2007.11.006 Boger, 2000, Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide, Proceedings of the National Academy of Sciences, United States of America, 97, 5044, 10.1073/pnas.97.10.5044 Bonhomme-Faivre, 2008, Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein, Addiction Biology, 13, 295, 10.1111/j.1369-1600.2008.00096.x Bornheim, 1995, Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain, Drug Metabolism and Disposition, 23, 825 Brooks, 2002, Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors, European Journal of Pharmacology, 439, 83, 10.1016/S0014-2999(02)01369-9 Brown, 1994, Pathophysiology of spasticity, Journal of Neurology, Neurosurgery & Psychiatry, 57, 773, 10.1136/jnnp.57.7.773 CAMMS223 Trial Investigators, 2008, Alemtuzumab vs. interferon beta-1a in early multiple sclerosis, New England Journal of Medicine, 359, 1786, 10.1056/NEJMoa0802670 Cabranes, 2005, Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis, Neurobiology of Disease, 20, 207, 10.1016/j.nbd.2005.03.002 Chevaleyre, 2006, Endocannabinoid-mediated synaptic plasticity in the CNS, Annual Review of Neuroscience, 29, 37, 10.1146/annurev.neuro.29.051605.112834 Clark, 2004, Patterns of cannabis use among patients with multiple sclerosis, Neurology, 62, 2098, 10.1212/01.WNL.0000127707.07621.72 Coles, 1999, Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis, Annals of Neurology, 46, 296, 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-# Collin, 2007, Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis, European Journal of Neurology, 14, 290, 10.1111/j.1468-1331.2006.01639.x Comelli, 2007, The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation, British Journal of Pharmacology, 152, 787, 10.1038/sj.bjp.0707425 Centonze, 2007, The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis, Brain, 130, 2543, 10.1093/brain/awm160 Centonze, 2009, Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis, Neurological Sciences, 30, 531, 10.1007/s10072-009-0136-5 Collin, 2010, A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis, Neurological Research, 32, 451, 10.1179/016164109X12590518685660 Compston, 2002, Multiple sclerosis, Lancet, 359, 1221, 10.1016/S0140-6736(02)08220-X Compston, 2008, Multiple sclerosis, Lancet, 372, 1502, 10.1016/S0140-6736(08)61620-7 Consroe, 1997, The perceived effects of smoked cannabis on patients with multiple sclerosis, European Neurology, 38, 44, 10.1159/000112901 Conte, 2009, Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis, European Journal of Pain, 13, 472, 10.1016/j.ejpain.2008.05.014 Cravatt, 2002, The enzymatic inactivation of the fatty acid amide class of signaling lipids, Chemistry and Physics of Lipids, 121, 135, 10.1016/S0009-3084(02)00147-0 Croxford, 2008, Cannabinoid-mediated neuroprotection, not immunosuppression, may be relevant to multiple sclerosis, Journal of Neuroimmunology, 193, 120, 10.1016/j.jneuroim.2007.10.024 de Lago, 2006, UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders, European Neuropsychopharmacology, 16, 7, 10.1016/j.euroneuro.2005.06.001 de Lago, 2004, In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake, European Journal of Pharmacology, 484, 249, 10.1016/j.ejphar.2003.11.027 Deutsch, 2002, The fatty acid amide hydrolase (FAAH), Prostaglandins, Leukotrienes and Essential Fatty Acids, 66, 201, 10.1054/plef.2001.0358 Devane, 1988, Determination and characterization of a cannabinoid receptor in rat brain, Molecular Pharmacology, 34, 605 Devane, 1992, Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science, 258, 1946, 10.1126/science.1470919 Diana, 2004, Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE), British Journal of Pharmacology, 142, 9, 10.1038/sj.bjp.0705726 Dinh, 2002, A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation, Chemistry and Physics of Lipids, 121, 149, 10.1016/S0009-3084(02)00150-0 Di Marzo, 2008, Endocannabinoids: synthesis and degradation, Reviews of Physiology, Biochemistry and Pharmacology, 160, 1, 10.1007/112_0505 Di Marzo, 2008, FAAH and anandamide: is 2-AG really the odd one out?, Trends in Pharmacological Sciences, 29, 229, 10.1016/j.tips.2008.03.001 Di Pasquale, 2009, The insertion and transport of anandamide in synthetic lipid membranes are both cholesterol-dependent, PLoS One, 4, e4989, 10.1371/journal.pone.0004989 Docagne, 2007, Excitotoxicity in a chronic model of multiple sclerosis: neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation, Molecular and Cellular Neuroscience, 34, 551, 10.1016/j.mcn.2006.12.005 Drew, 2008, Glutamate spillover modulates GABAergic synaptic transmission in the rat midbrain periaqueductal grey via metabotropic glutamate receptors and endocannabinoid signaling, Journal of Neuroscience, 28, 808, 10.1523/JNEUROSCI.4876-07.2008 Dutta, 2006, Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients, Annals of Neurology, 59, 478, 10.1002/ana.20736 Dutta, 2007, Pathogenesis of axonal and neuronal damage in multiple sclerosis, Neurology, 68, S22, 10.1212/01.wnl.0000275229.13012.32 Dziadulewicz, 2007, Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration, Journal of Medicinal Chemistry, 50, 3851, 10.1021/jm070317a Dyson, 2005, Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat, Pain, 116, 129, 10.1016/j.pain.2005.03.037 Eljaschewitsch, 2006, The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells, Neuron, 49, 67, 10.1016/j.neuron.2005.11.027 El-Remessy, 2003, Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite, American Journal of Pathology, 163, 1997, 10.1016/S0002-9440(10)63558-4 Franklin, 2003, Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors, European Journal of Pharmacology, 474, 195, 10.1016/S0014-2999(03)02074-0 Freeman, 2006, The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS), International Urogynecology Journal and Pelvic Floor Dysfunction, 17, 636, 10.1007/s00192-006-0086-x Fu J, Bottegoni G, Sasso O, Bertorelli R, Rocchia W, Masetti M, et al. A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nature Neuroscience 2011 (November 20). doi:10.1038/nn.2986 [Epub]. Gao, 2010, Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice, Journal of Neuroscience, 30, 2017, 10.1523/JNEUROSCI.5693-09.2010 Giovannoni, 2010, A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis, New England Journal of Medicine, 362, 416, 10.1056/NEJMoa0902533 Glaser, 2003, Evidence against the presence of an anandamide transporter, Proceedings of the National Academy of Sciences of the United States of America, 100, 4269, 10.1073/pnas.0730816100 Guo, 2004, Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons, Molecular Pharmacology, 65, 665, 10.1124/mol.65.3.665 Hampson, 1998, Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants, Proceedings of the National Academy of Sciences of the United States of America, 95, 8268, 10.1073/pnas.95.14.8268 Hampton, 2008, An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss, Journal of Neuroimmunology, 201–202, 200, 10.1016/j.jneuroim.2008.05.034 Hashimotodani, 2008, Pharmacological evidence for the involvement of diacylglycerol lipase in depolarization-induced endocanabinoid release, Neuropharmacology, 54, 58, 10.1016/j.neuropharm.2007.06.002 Hasseldam, 2010, Neuroprotection without immunomodulation is not sufficient to reduce first relapse severity in experimental autoimmune encephalomyelitis, Neuroimmunomodulation, 17, 252, 10.1159/000290041 Hasseldam, 2011, Cannabinoid treatment renders neurons less vulnerable than oligodendrocytes in experimental autoimmune encephalomyelitis, International Journal of Neuroscience, 10.3109/00207454.2011.582237 Hayakawa, 2008, Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism, Brain Research, 1188, 157, 10.1016/j.brainres.2007.09.090 Hayakawa, 2007, Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism, Journal of Neurochemistry, 102, 1488, 10.1111/j.1471-4159.2007.04565.x Herkenham, 1990, Cannabinoid receptor localization in brain, Proceedings of the National Academy of Sciences of the United States of America, 87, 1932, 10.1073/pnas.87.5.1932 Hermann, 2006, 2-Arachidonoylglycerol (2-AG) membrane transport: history and outlook, AAPS Journal, 8, E409, 10.1208/aapsj080247 Holland, 2007, The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids, British Journal of Pharmacology, 152, 815, 10.1038/sj.bjp.0707467 Holland, 2008, Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1), European Journal of Pharmacology, 591, 128, 10.1016/j.ejphar.2008.06.079 Hollister, 1975, Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol, Clinical Pharmacology & Therapeutics, 18, 80, 10.1002/cpt197518180 Honarmand, 2011, Effects of cannabis on cognitive function in patients with multiple sclerosis, Neurology, 76, 1153, 10.1212/WNL.0b013e318212ab0c Howlett, 1985, Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes, Molecular Pharmacology, 27, 429 Howlett, 2002, International Union of Pharmacology. XXVII. Classification of cannabinoid receptors, Pharmacological Reviews, 54, 161, 10.1124/pr.54.2.161 Howlett, 2011, Endocannabinoid tone versus constitutive activity of cannabinoid receptors, British Journal of Pharmacology, 163, 1329, 10.1111/j.1476-5381.2011.01364.x Huestis, 2007, Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users, Psychopharmacology, 194, 505, 10.1007/s00213-007-0861-5 Huestis, 2001, Blockade of effects of smoked marijuana by the CB1-selective c annabinoid receptor antagonist SR141716, Archives of General Psychiatry, 58, 322, 10.1001/archpsyc.58.4.322 Iskedjian, 2007, Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain, Current Medical Research and Opinion, 23, 17, 10.1185/030079906X158066 Izzo, 2009, Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb, Trends in Pharmacological Sciences, 30, 515, 10.1016/j.tips.2009.07.006 Jackson, 2005, Cannabinoid receptor null mice are susceptible to neurofilament damage and caspase 3 activation, Neuroscience, 134, 261, 10.1016/j.neuroscience.2005.02.045 Jarrahian, 2000, Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter, Journal of Neurochemistry, 74, 2597, 10.1046/j.1471-4159.2000.0742597.x Jayamanne, 2006, Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models, British Journal of Pharmacology, 147, 281, 10.1038/sj.bjp.0706510 Jung, 2007, A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization, Molecular Pharmacology, 72, 612, 10.1124/mol.107.037796 Karschner, 2011, Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration, Clinical Chemistry, 57, 66, 10.1373/clinchem.2010.152439 Katona, 2008, Endocannabinoid signaling as a synaptic circuit breaker in neurological disease, Nature Medicine, 14, 923, 10.1038/nm.f.1869 Katona, 2005, Cannabinoid influence on cytokine profile in multiple sclerosis, Clinical and Experimental Immunology, 140, 580, 10.1111/j.1365-2249.2005.02803.x Kavia, 2010, Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis, Multiple Sclerosis, 16, 1349, 10.1177/1352458510378020 Killestein, 2003, Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis, Journal of Neuroimmunology, 137, 140, 10.1016/S0165-5728(03)00045-6 Kim, 2006, AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis, European Journal of Pharmacology, 542, 100, 10.1016/j.ejphar.2006.05.025 Klegeris, 2003, Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor, British Journal of Pharmacology, 139, 775, 10.1038/sj.bjp.0705304 Kmietowicz, 2010, Cannabis based drug is licensed for spasticity in patients with MS, British Medical Journal, 340, c3363, 10.1136/bmj.c3363 Kooij, 2010, T lymphocytes impair P-glycoprotein function during neuroinflammation, Journal of Autoimmunity, 34, 416, 10.1016/j.jaut.2009.10.006 Kozela, 2011, Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice, British Journal of Pharmacology, 163, 1507, 10.1111/j.1476-5381.2011.01379.x Kreitzer, 2001, Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells, Neuron, 29, 717, 10.1016/S0896-6273(01)00246-X Leung, 2006, Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids, Biochemistry, 45, 4720, 10.1021/bi060163l Lichtman, 2002, Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo, Journal of Pharmacology and Experimental Therapeutics, 302, 73, 10.1124/jpet.302.1.73 Ligresti, 2006, New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis, British Journal of Pharmacology, 147, 83, 10.1038/sj.bjp.0706418 Liu, 2008, Multiple pathways involved in the biosynthesis of anandamide, Neuropharmacology, 54, 1, 10.1016/j.neuropharm.2007.05.020 Long, 2009, Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects, Nature Chemical Biology, 5, 37, 10.1038/nchembio.129 Loría, 2010, An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis, Neurobiology of Disease, 37, 166, 10.1016/j.nbd.2009.09.020 Lourbopoulos, 2011, Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis, Brain Research, 1390, 126, 10.1016/j.brainres.2011.03.020 Ludányi, 2011, Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus, Neuroscience, 174, 50, 10.1016/j.neuroscience.2010.10.062 Lyman, 1989, Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis, Journal of Neuroimmunology, 23, 73, 10.1016/0165-5728(89)90075-1 Maccarrone, 2008, Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum, Nature Neuroscience, 11, 152, 10.1038/nn2042 Maejima, 2001, Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors, Neuron, 31, 463, 10.1016/S0896-6273(01)00375-0 Maresz, 2007, Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T Cells, Nature Medicine, 13, 492, 10.1038/nm1561 Marrs, 2010, The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors, Nature Neuroscience, 13, 951, 10.1038/nn.2601 Matsuda, 1990, Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature, 346, 561, 10.1038/346561a0 Mechoulam, 1995, Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors, Biochemical Pharmacology, 50, 83, 10.1016/0006-2952(95)00109-D Mechoulam, 1967, The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish, Tetrahedron Letters, 12, 1109, 10.1016/S0040-4039(00)90646-4 Mestre, 2009, A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules, Molecular and Cellular Neuroscience, 40, 258, 10.1016/j.mcn.2008.10.015 Nagayama, 1999, Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures, Journal of Neuroscience, 19, 2987, 10.1523/JNEUROSCI.19-08-02987.1999 Nielsen, 2007, The spinal pathophysiology of spasticity—from a basic science point of view, Acta Physiologica, 189, 171, 10.1111/j.1748-1716.2006.01652.x Notcutt, 2011, A placebo-controlled, parallel-group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(R) (nabiximols), Multiple Sclerosis Novotna, 2011, A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis, European Journal of Neurology, 18, 1122, 10.1111/j.1468-1331.2010.03328.x Nyilas, 2008, Enzymatic machinery for endocannabinoid biosynthesis associated with calcium stores in glutamatergic axon terminals, Journal of Neuroscience, 28, 1058, 10.1523/JNEUROSCI.5102-07.2008 Oshiro, 2010, Suppression of stretch reflex activity after spinal or systemic treatment with AMPA receptor antagonist NGX424 in rats with developed baclofen tolerance, British Journal of Pharmacology, 161, 976, 10.1111/j.1476-5381.2010.00954.x Oudin, 2011, Endocannabinoids regulate the migration of subventricular zone-derived neuroblasts in the postnatal brain, Journal of Neuroscience, 31, 4000, 10.1523/JNEUROSCI.5483-10.2011 Palazuelos, 2008, The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis, Journal of Biological Chemistry, 283, 13320, 10.1074/jbc.M707960200 Pan, 2009, Blockade of 2-AG hydrolysis by selective monoacylglycerol lipase inhibitor JZL184 enhances retrograde endocannabinoid signaling, Journal Of Pharmacology and Experimental Therapeutics, 10.1124/jpet.109.158162 Panikashvili, 2001, An endogenous cannabinoid (2-AG) is neuroprotective after brain injury, Nature, 413, 527, 10.1038/35097089 Parmentier-Batteur, 2002, Increased severity of stroke in CB1 cannabinoid receptor knock-out mice, Journal of Neuroscience, 22, 9771, 10.1523/JNEUROSCI.22-22-09771.2002 Patel, 2010, The evaluation of the effects of Sativex® (THC:CBD) on the inhibition of spasticity in an experimental model of multiple sclerosis, Multiple Sclerosis, 16, S234 Patel, 2005, The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity, Journal of Lipid Research, 46, 342, 10.1194/jlr.M400377-JLR200 Pertwee, 1999, Pharmacology of cannabinoid receptor ligands, Current Medicinal Chemistry, 6, 635, 10.2174/0929867306666220401124036 Pertwee, 2008, The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin, British Journal of Pharmacology, 153, 199, 10.1038/sj.bjp.0707442 Pertwee, 2010, International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2, Pharmacological Reviews, 62, 588, 10.1124/pr.110.003004 Polman, 2006, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, New England Journal of Medicine, 354, 899, 10.1056/NEJMoa044397 Pryce, 2003, Cannabinoids inhibit neurodegeneration in models of multiple sclerosis, Brain, 126, 2191, 10.1093/brain/awg224 Pryce, 2007, Control of Spasticity in a Multiple Sclerosis Model is CB1, not CB2, cannabinoid receptor mediated, British Journal of Pharmacology, 150, 519, 10.1038/sj.bjp.0707003 Pryce, 2005, Immunological tolerance that eliminates relapses, fails to halt secondary progression in a chronic multiple sclerosis model, Journal of Neuroimmunology, 165, 41, 10.1016/j.jneuroim.2005.04.009 Rachelefsky, 1976, Intact humoral and cell-mediated immunity in chronic marijuana smoking, Journal of Allergy and Clinical Immunology, 58, 483, 10.1016/0091-6749(76)90192-5 Ralevic, 2001, Cannabinoid activation of recombinant and endogenous vanilloid receptors, European Journal of Pharmacology, 424, 211, 10.1016/S0014-2999(01)01153-0 Ransohoff, 2006, EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis, Trends in Immunology, 27, 167, 10.1016/j.it.2006.02.007 Rice, 2000, Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group, Neurology, 54, 1145, 10.1212/WNL.54.5.1145 Robson, 2011, Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine, Expert Opinion on Drug Safety, 10.1517/14740338.2011.575778 Rog, 2005, Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis, Neurology, 65, 812, 10.1212/01.wnl.0000176753.45410.8b Rog, 2007, Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial, Clinical Therapeutics, 29, 2068, 10.1016/j.clinthera.2007.09.013 Rossi, 2011, Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis, Brain Behavior and Immunity, 25, 1242, 10.1016/j.bbi.2011.03.017 Rossi, 2009, Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis, Neurobiology of Disease, 36, 51, 10.1016/j.nbd.2009.06.013 Rubio-Araiz, 2008, The endocannabinoid system modulates a transient TNF pathway that induces neural stem cell proliferation, Molecular and Cellular Neuroscience, 38, 374, 10.1016/j.mcn.2008.03.010 Russo, 2006, A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol, Medical Hypotheses, 66, 234, 10.1016/j.mehy.2005.08.026 Schabitz, 2002, Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study, Stroke, 33, 2112, 10.1161/01.STR.0000023491.63693.18 Smith, 2000, Autoimmune encephalomyelitis ameliorated by AMPA antagonists, Nature Medicine, 6, 62, 10.1038/71548 Smith, 2001, Electrically active axons degenerate when exposed to nitric oxide, Annals of Neurology, 49, 470, 10.1002/ana.96 Shakespeare, 2003, Anti-spasticity agents for multiple sclerosis, Cochrane Database of Systematic Reviews, 4, CD001332 Simon, 2006, Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway, Journal of Biological Chemistry, 281, 26465, 10.1074/jbc.M604660200 Simon, 2008, Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain, Journal of Biological Chemistry, 283, 9341, 10.1074/jbc.M707807200 Schlosburg, 2010, Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system, Nature Neuroscience, 13, 1113, 10.1038/nn.2616 Sriram, 2005, Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis, Annals of Neurology, 58, 939, 10.1002/ana.20743 Szabo, 2006, Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol, Journal of Physiology, 577, 263, 10.1113/jphysiol.2006.119362 Tagliaferro, 2006, Neuronal cytoskeleton and synaptic densities are altered after a chronic treatment with the cannabinoid receptor agonist WIN 55,212-2, Brain Research, 1085, 163, 10.1016/j.brainres.2005.12.089 Tanimura, 2010, The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission, Neuron, 65, 320, 10.1016/j.neuron.2010.01.021 Thomas, 2007, Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro, British Journal of Pharmacology, 150, 613, 10.1038/sj.bjp.0707133 Tsuboi, 2011, Enzymatic formation of N-acylethanolamines from N-acylethanolamine plasmalogen through N-acylphosphatidylethanolamine-hydrolyzing phospholipase D-dependent and -independent pathways, Biochimica et Biophysica Acta, 1811, 565, 10.1016/j.bbalip.2011.07.009 Ueda, 2011, Biosynthesis and degradation of the endocannabinoid 2-arachidonoylglycerol, Biofactors, 37, 1, 10.1002/biof.131 Varvel, 2005, Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice, Journal of Pharmacology and Experimental Therapeutics, 314, 329, 10.1124/jpet.104.080739 Varvel, 2006, Interactions between THC and cannabidiol in mouse models of cannabinoid activity, Psychopharmacology (Berlin), 186, 226, 10.1007/s00213-006-0356-9 Wade, 2006, Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis, Multiple Sclerosis, 12, 639, 10.1177/1352458505070618 Wade, 2010, Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis, Multiple Sclerosis, 16, 707, 10.1177/1352458510367462 Wang, 2008, The functional regulation of TRPV1 and its role in pain sensitization, Neurochemical Research, 33, 2008, 10.1007/s11064-008-9750-5 Webb, 2008, Genetic deletion of fatty acid amide hydrolase results in improved long-term outcome in chronic autoimmune encephalitis, Neuroscience Letters, 439, 106, 10.1016/j.neulet.2008.04.090 Wilkinson, 2003, Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects?, Journal of Pharmacy and Pharmacology, 55, 1687, 10.1211/0022357022304 Wilson, 2001, Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses, Nature, 410, 588, 10.1038/35069076 Wilson, 2002, Endocannabinoid signaling in the brain, Science, 296, 678, 10.1126/science.1063545 Witting, 2006, Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection, Proceedings of the National Academy of Sciences USA, 103, 6362, 10.1073/pnas.0510418103 Zajicek, 2011, Role of cannabinoids in multiple sclerosis, CNS Drugs, 25, 187, 10.2165/11539000-000000000-00000 Zajicek, 2003, Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial, Lancet, 362, 1517, 10.1016/S0140-6736(03)14738-1 Zajicek, 2005, Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up, Journal of Neurology, Neurosurgery, and Psychiatry, 76, 1664, 10.1136/jnnp.2005.070136 Zhang, 2009, Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke, Journal of Neuroimmune Pharmacology, 4, 249, 10.1007/s11481-009-9148-4 Zhu, 2006, Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana, Journal of Pharmacology and Experimental Therapeutics, 317, 850, 10.1124/jpet.105.098541